why us authorises second covid-19 booster for americans 50 and above

The U.S. approves a second COVID-19 accelerator for Americans age 50 and older

second-covid-19-booster


The impulse shot will be given at least four months after the previous dose


The decision to offer two accelerators in the United States comes because some scientists have raised concerns about the most contagious sub-variance and new well-being of BA.2 Omicron, which has led to COVID-19 cases in other countries.

U.S. health officials on Tuesday approved a second booster dose of COVID-19 from the two most common COVID-19 vaccines for people 50 and older, citing data showing declining immunity and the risks posed by Omicron versions of the virus.

The U.S. Food and Drug Administration said the new boosters - a fourth-round shot for most vaccine recipients - of vaccines Pfizer Inc / BioNTech SE and Moderna Inc should be given after four months from the previous dose. They are designed to offer more protection against serious illness and hospitalization.

The FDA has also approved a second booster dose of vaccines for younger people with compromised immune systems - aged 12 and over for a Pfizer / BioNTech injection and 18 or older for Moderna's.

The U.S. Centers for Disease Control and Prevention (CDC) supported FDA approval, and recommended the additional injection, especially for the elderly and those with basic medical conditions that put them at higher risk.

The decision to offer two accelerators in the United States comes because some scientists have raised concerns about the most contagious sub-variance and new well-being of BA.2 Omicron, which has led to COVID-19 cases in other countries.

"If these were my relatives, I would send them to do it," an FDA official, Dr. Peter Marks, said during a press conference about receiving booster shots. "COVID-19 had a really disproportionate negative effect on people. People aged 65 and over and those with comorbidities. "COVID cases in the United States have fallen sharply since a record rise in January, but have seen a small increase over the past week, according to CDC data.


A broader campaign may be needed

The FDA said it was examining dMarx said the FDA will soon consider the benefits of approving another round of accelerators - perhaps specifically targeted to combat new versions of concern - for a wider population after the summer.

"Individuals might get greater support in the fall alongside a more broad support crusade, assuming that that occurs, in light of the fact that we might need to move to an alternate variation inclusion," he said.

ATA from a relatively small and ongoing clinical trial in Israel to help make the decision. In addition, safety data from more than 700,000 people who received two accelerators in Israel did not reveal any new concerns, the agency said.

Scientists and officials have been debating for months whether and when another impulse shot will be required while they analyze data on the duration of protection against vaccines and accelerators.

"It's not clear now is the right time for people to have a fourth dose," said Dr. William Moss, director of the International Center for Vaccine Access at the Johns Hopkins Bloomberg School of Public Health.

If there is an increase in cases in late fall or early winter, as is typical of respiratory and flu viruses, further reinforcement may be needed, he said. The body's neutralizing antibodies, driven by a fourth impulse now given, may drop in just a few months, he said.

It is also unclear whether young and healthy will need a fourth shot. The study on Israeli health workers cited by the FDA suggested that the fourth dose added a little extra protection in the age group.

Senior Biden administration officials say the U.S. government currently has enough doses of vaccines to meet the demand for another round of push shots in older Americans, even though funding for the U.S. epidemic response has almost run out.

They say that if Congress does not approve additional spending, the government will not be able to pay for future vaccines, if needed, especially if it is necessary to redesign the vaccines so that they focus on new versions.

About two-thirds of Americans who are fully vaccinated over age 65 and just over half of people between the ages of 50 and 64 have received their first booster dose to date.

Post a Comment

0 Comments